H.C. Wainwright resumed coverage on Terns Pharmaceuticals
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright resumed coverage of Terns Pharmaceuticals with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2025 | $20.00 | Buy | Truist |
| 9/17/2025 | $15.00 | Overweight | Barclays |
| 9/4/2025 | Neutral | H.C. Wainwright | |
| 2/28/2025 | Mkt Perform | William Blair | |
| 10/31/2024 | $82.00 | Outperform | Oppenheimer |
| 6/22/2023 | $16.00 | Buy | Mizuho |
| 6/7/2023 | $18.00 | Buy | Jefferies |
| 5/31/2023 | $23.00 | Buy | ROTH MKM |
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leukemia with clinical data this quarter FOSTER CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of sm
FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment
FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release expected in fourth quarter of 2025. The webinar will review TERN-701's potential best-in-class profile, relevant benchmarks for upcoming Phase 1 data and positioning in an evolving treatment landscape for chronic myeloid leukemia (CML). TERN-701 is an investigational next-generation oral, allosteric BCR
Truist initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Barclays initiated coverage of Terns Pharmaceuticals with a rating of Overweight and set a new price target of $15.00
H.C. Wainwright resumed coverage of Terns Pharmaceuticals with a rating of Neutral
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
10-Q - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor
FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from
TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)